Clinical Characteristics of Patients Studied Before or After Allogeneic BMT for Thalassemia Major
| . | Studied Before Transplantation . | Studied After Transplantation . | All Patients . |
|---|---|---|---|
| N | 20 | 23 | 43 |
| Age (yr) | 17 ± 6 | 17 ± 4 | 17 ± 5 |
| Years after BMT | — | 5 ± 3 | — |
| Years of transfusion therapy | 17 ± 6 | 10 ± 5* | 13 ± 6 |
| Age at first transfusion (mo) | 10 ± 8 | 23 ± 30 | 18 ± 24 |
| Transfusions received | 361 ± 153 | 164 ± 108* | 243 ± 160 |
| Serum ferritin ( μg/L) | 2,699 ± 1,962 | 1,391 ± 1,718 | 1,914 ± 1,904 |
| Anti-HCV antibody positive | 14 | 17 | 31 |
| . | Studied Before Transplantation . | Studied After Transplantation . | All Patients . |
|---|---|---|---|
| N | 20 | 23 | 43 |
| Age (yr) | 17 ± 6 | 17 ± 4 | 17 ± 5 |
| Years after BMT | — | 5 ± 3 | — |
| Years of transfusion therapy | 17 ± 6 | 10 ± 5* | 13 ± 6 |
| Age at first transfusion (mo) | 10 ± 8 | 23 ± 30 | 18 ± 24 |
| Transfusions received | 361 ± 153 | 164 ± 108* | 243 ± 160 |
| Serum ferritin ( μg/L) | 2,699 ± 1,962 | 1,391 ± 1,718 | 1,914 ± 1,904 |
| Anti-HCV antibody positive | 14 | 17 | 31 |
Values shown are the mean ± SD.
Abbreviation: BMT, bone marrow transplantation.
Before bone marrow transplantation.